Evaluation of SCF-engineered particle-based lactose blends in passive dry powder inhalers

International Journal of Pharmaceutics

Volumn 281, Issue 1-2, 2004, Pages 55-66

  Schiavone, Helena ^a   Palakodaty, Srinivas ^a   Clark, Andy ^b   York, Peter ^b   Tzannis, Stelios T ^a  

^a NEKTAR THERAPEUTICS   (United States)

^b Campus Road BD7 1HR   (United Kingdom)

Author keywords

Dry powder inhaler; Lactose blends; Micronization; Pulmonary delivery; Supercritical fluids

Indexed keywords

BUDESONIDE; GRANULAC; INHALAC; LACTOSE; PRISMALAC; SALBUTAMOL SULFATE; SORBOLAC; SPHEROLAC; UNCLASSIFIED DRUG;

AEROSOL; ARTICLE; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SCREENING; DRY POWDER; POWDER INHALER; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SUPERCRITICAL FLUID;

ADMINISTRATION, INHALATION; ALBUTEROL; BUDESONIDE; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, SUPERCRITICAL FLUID; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; FORECASTING; GREAT BRITAIN; LACTOSE; METERED DOSE INHALERS; MICROSCOPY, ELECTRON, SCANNING; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; POWDERS;

EID: 3543128402     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2004.05.029     Document Type: Article

References (42)

1. Barrowcliffe, J., McGlynn, P., Ratcliffe, S., Sewell, M., Sheikh S., Walters, M., 1998. Beclomethasone dipropionate (BDP) Clickhaler: in vitro performance of a steroid novel dry powder inhaler. Proc. Drug Del. Lungs VIII, 125-128.
2. Bell J.H., Hartley P.S., Cox J.S.G. Dry powder aerosols. I. A new powder inhalation device. J. Pharm. Sci. 60:1971;1559-1564
3. Clarke M.J., Tobyn M.J., Staniforth J.N. The formulation of powder inhalation systems containing a high mass of nedocromil sodium trihydrate. J. Pharm. Sci. 90:2001;213-223
4. Draco R.S., Vogel G.C., Needham T.E. A four-parameter equation for predicting enthalpies of adduct formation. J. Am. Chem. Soc. 93:1971;6014-6026
5. Dunbar C.A., Hickey A.J., Holzner P. Dispersion and characterization of pharmaceutical dry powder aerosols. KONA. 16:1998;7-45
6. Feeley J.C. Powder characterization tests: Can they make a difference in product development? Resp. Drug Del. VIII:2002;295-301
7. Feeley J.C., York P., Sumby B.S., Dicks H. Determination of surface properties and flow characteristics of salbutamol sulfate before and after micronization. Int. J. Pharm. 172:1998;89-96
8. Ganderton, D., Kassem, N.M., 1992. Dry powder inhalers. In: Advances in Pharmaceutical Sciences, vol. 6. Academic Press, London, pp. 165-191.
9. Gutmann, V., 1978. The Donor-Acceptor Approach to Molecular Interactions. Plenum Press, New York, London.
10. Hanna, M., York, P., 1994. Method and apparatus for the formation of particles. UK Patent No. PCT/GB94/01426.
11. Hersey J.A. Ordered mixing: a new concept in powder mixing practice. Powder Technol. 11:1975;41-44
12. Jung J., Perrut M. Particle design using supercritical fluids: literature and patent survey. J. Supercr. Fluids. 20:2001;179-219
13. Kassem N.M., Ganderton D. The influence of carrier surface on the characteristics of inspirable powder aerosols. J. Pharm. Pharmacol. 42:1990;11
14. Kawashima Y., Serigano T., Hino T., Yamamoto H., Takeuchi H. Effect of surface morphology of carrier lactose on dry powder inhalation property of Pranlukast hydrate. Int. J. Pharm. 172:1998;179-188
15. Larhib H., Zeng X.M., Martin G., Marriott C., Pritchard J. The use of different grades of lactose as carrier for aerosolized salbutamol sulphate. Int. J. Pharm. 191:1999;1-14
16. Lobo, J., Schiavone, H., Palakodaty, S., York, P., Tzannis, S.T., 2003. SCF-engineered powders improve pulmonary delivery of budesonide from passive DPI devices, Pharm. Res., submitted for publication.
17. Lord, J.D., 1993. Particle interactions in dry powder inhalations, Doctoral Thesis, University of Bath.
18. Malcolmson R.J., Embleton J.K. Dry powder formulations for pulmonary delivery. Pharm. Sci. Technol. Today. 1:1998;394-398
19. Meakin B.J., Woodcock P.M., Segu A., Niccolai F., Vecchio C. Evaluation of the resistance to airflow through Turbospin in comparison with dry powder inhalers available on the market. Boll. Chim. Farmaceutico-Anno. 135:1996;107-109
20. Palakodaty S., York P., Pritchard J. Supercritical fluid processing of materials from aqueous solutions: the application of SEDS to lactose as a model substance. Pharm. Res. 15:1998;1835-1843
21. Palakodaty, S., Walker, S., Townend, G., York, P., Humphreys, G., 2000. Scale Up and GMP Plant Design - Pharmaceutical Particle Engineering by the SEDS Process. Eur. Pharm. Contr., August, pp. 60-63.
22. Podczeck F. The relationship between physical properties of lactose monohydrate and the aerodynamic behaviour of adhered drug particles. Int. J. Pharm. 160:1998;119-130
23. Price R., Young P.M., Tobyn M.J. DPI powder adhesion properties: the power of AFM. Resp. Drug Delivery. VIII:2000;285-294
24. Price R., Young P.M., Edge S., Staniforth J.N. The influence of relative humidity on particulate interactions in carrier-based dry powder inhaler formulations. Int. J. Pharm. 246:2002;47-59
25. Schultz, J., Lavielle, L., 1989. Interfacial properties of carbon fiber-epoxy matrix composites. In: Lloyd, D.R., Ward, T.C., Schreiber, H.P. (Eds.), Inverse Gas Chromatography Characterization of Polymers and Other Materials, ACS Symposium Series, vol. 391. The American Chemical Society, Washington, DC, pp. 185-202.
26. Smith R.J., Haken J.K., Wainwright M.S. Evaluation of mathematical procedures for the calculation of dead time. J. Chromatogr. 147:1978;65-73
27. Staniforth J. Pre-formulation aspects of dry powder aerosols. Resp. Drug Del. V:1996;65-73
28. Staniforth J.N., Rees J.E., Lai F.K., Hersey J.A. Interparticle forces in binary and tertiary ordered powder mixes. J. Pharm. Pharmacol. 34:1982;141-145
29. Steckel M., Müller B.W. In vitro evaluation of dry powder inhalers. I. In vitro deposition of commonly used devices. Int. J. Pharm. 154:1997;19-29
30. Steckel M., Müller B.W. In vitro evaluation of dry powder inhalers. II. Influence of carrier particle size and concentration on in vitro deposition. Int. J. Pharm. 154:1997;31-37
31. Ticehurst M.D., Rowe R.C., York P. Determination of the surface properties of two batches of salbutamol sulphate by inverse gas chromatography. Int. J. Pharm. 111:1994;241-249
32. Timsina M., Martin G., Marriott C., Ganderon D., Yanneskis M. Drug delivery to the respiratory track using dry powder inhalers. Int. J. Pharm. 101:1994;1-13
33. Tom J.W., Debenedetti P.G. Particle formation in supercritical fluids: a review. J. Aerosol Sci. 22:1991;555-564
34. Tong H.H.Y., Shekunov B.Y., York P., Chow A.H.L. Influence of polymorphism on the surface energetics of salmeterol xinafoate crystallized from supercritical fluids. Pharm. Res. 19:2002;640-648
35. Vachon M.G., Chulia D. The use of particle characteristics to elucidate mix homogeneity in binary powder blends. Drug Dev. Ind. Pharm. 24:1998;961-971
36. Van Oort M.M., Dawney B., Roberts W. Verification of operating the Andersen cascade impactor at different flow rates. Pharm. Forum. 22:1996;2211-2215
37. Vidgren M., Arppe J., Vidgren P., Vainio P., Silvasti M., Tukiainen H. Pulmonary deposition or 99mTc-labelled salbutamol particles in healthy volunteers after inhalation from a metered-dose inhaler and a novel multiple-dose inhaler. Stp. Pharm. Sci. 4:1994;29-32
38. Ward G.H., Schultz R.K. Process-induced crystallinity changes in albuterol sulfate and its effect on powder physical stability. Pharm. Res. 12:1995;773-779
39. Yeung C., Hersey J. Ordered powder mixing of coarse and fine particulate systems. Powder Technol. 22:1979;127-131
40. York, P., 2003. Crystal engineering and particle design for drug delivery. In: Proceedings of the 30th Annual Controlled Release Society Meeting and Exhibition, Glasgow, July 19-23.
41. Zeng X.M., Martin G.P., Tee S., Marriott C. The role of fine particle lactose on the dispersion and deaggregation of salbutamol sulphate in an air stream in vitro. Int. J. Pharm. 176:1998;99-110
42. Zeng X.M., Pandhal K., Martin G. The influence of lactose carrier on the content homogeneity and dispersibility of beclomethasone dipropionate from dry powder aerosols. Int. J. Pharm. 197:2000;41-52